Susceptibility-weighted MR imaging in the grading of liver fibrosis: A feasibility study

Radiology

Volumn 270, Issue 1, 2014, Pages 149-158

  Balassy, Csilla ^a   Feier, Diana ^a,b   Peck Radosavljevic, Markus ^a   Wrba, Friedrich ^a   Witoszynskyj, Stephan ^a   Kiefer, Berthold ^c   Reiter, Gert ^d   Dai, Yongming ^e   Ba Ssalamah, Ahmed ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c SIEMENS AG   (Germany)

^d Siemens Healthcare   (Austria)

^e Siemens Healthcare   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FATTY LIVER; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SCORING SYSTEM; SIGNAL DETECTION; SUSCEPTIBILITY WEIGHTED IMAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; RETROSPECTIVE STUDIES;

EID: 84891107832     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122440     Document Type: Article

References (34)

1. Okazaki H, Ito K, Fujita T, Koike S, Takano K, Matsunaga N. Discrimination of alcoholic from virus-induced cirrhosis on MR imaging. AJR Am J Roentgenol 2000;175(6):1677-1681.
2. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10(3):459-479.
3. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008;12(4):733-746.
4. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140(4):1182-1188, e1.
5. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19(3):1-46.
6. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495-500.
7. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32(3):477-481.
8. Lewin M, Poujol-Robert A, Boëlle PY, et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46(3):658-665.
9. Pasquinelli F, Belli G, Mazzoni LN, et al. MR-diffusion imaging in assessing chronic liver diseases: does a clinical role exist? Radiol Med (Torino) 2012;117(2):242-253.
10. Bonekamp S, Torbenson MS, Kamel IR. Diffusion-weighted magnetic resonance imaging for the staging of liver fibrosis. J Clin Gastroenterol 2011;45(10):885-892.
11. Hagiwara M, Rusinek H, Lee VS, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 2008;246(3):926-934.
12. Wang Y, Ganger DR, Levitsky J, et al. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol 2011;196(3):553-561.
13. Lim AK, Patel N, Eckersley RJ, et al. A comparison of 31P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease. J Viral Hepat 2011;18(10):e530-e534.
14. Motosugi U, Ichikawa T, Oguri M, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011;29(8):1047-1052.
15. Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011;2011:443-450.
16. Chen W, DelProposto Z, Wu D, et al. Improved siderotic nodule detection in cirrhosis with susceptibility-weighted magnetic resonance imaging: a prospective study. PLoS ONE 2012;7(5):e36454.
17. Dai Y, Zeng M, Li R, et al. Improving detection of siderotic nodules in cirrhotic liver with a multi-breath-hold susceptibilityweighted imaging technique. J Magn Reson Imaging 2011;34(2):318-325.
18. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility- weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009;30(1): 19-30.
19. Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 2009;30(2):232-252.
20. Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am 2011;40(3):507-521.
21. Li RK, Zeng MS, Rao SX, et al. Using a 2D multibreath-hold susceptibility-weighted imaging to visualize intratumoral hemorrhage of hepatocellular carcinoma at 3T MRI: correlation with pathology. J Magn Reson Imaging 2012;36(4):900-906.
22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24(2):289-293.
23. Krinsky GA, Lee VS, Nguyen MT, et al. Siderotic nodules in the cirrhotic liver at MR imaging with explant correlation: no increased frequency of dysplastic nodules and hepatocellular carcinoma. Radiology 2001;218(1): 47-53.
24. Breitkopf K, Nagy LE, Beier JI, Mueller S, Weng H, Dooley S. Current experimental perspectives on the clinical progression of alcoholic liver disease. Alcohol Clin Exp Res 2009;33(10):1647-1655.
25. Pagliaro L, Rinaldi F, Craxì A, et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis: a prospective, randomized trial. Dig Dis Sci 1983;28(1):39-43.
26. Deugnier Y, Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 2007; 13(35):4755-4760.
27. Semelka RC, Chung JJ, Hussain SM, Marcos HB, Woosley JT. Chronic hepatitis: correlation of early patchy and late linear enhancement patterns on gadoliniumenhanced MR images with histopathology initial experience. J Magn Reson Imaging 2001;13(3):385-391.
28. Shim JH, Yu JS, Chung JJ, Kim JH, Kim KW. Segmental difference of the hepatic fibrosis from chronic viral hepatitis due to hepatitis B versus C virus infection: comparison using dual contrast material-enhanced MRI. Korean J Radiol 2011;12(4):431-438.
29. Kim MJ, Mitchell DG, Ito K, Kim JH, Pasqualin D, Rubin R. Hepatic iron deposition on magnetic resonance imaging: correlation with inflammatory activity. J Comput Assist Tomogr 2002;26(6):988-993.
30. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34(3):274-285.
31. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54(4):1208-1216.
32. Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease: MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012;36(1): 22-29.
33. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-1374.
34. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006; 239(2):425-437.